Amphastar Pharmaceuticals Stock Earnings Reports
Amphastar Pharmaceuticals Earnings Calls
Release date | May 07, 2025 |
EPS estimate | $0.660 |
EPS actual | $0.740 |
EPS Surprise | 12.12% |
Revenue estimate | 173.056M |
Revenue actual | 170.528M |
Revenue Surprise | -1.46% |
Release date | Feb 27, 2025 |
EPS estimate | $1.01 |
EPS actual | $0.92 |
EPS Surprise | -8.91% |
Revenue estimate | 188.777M |
Revenue actual | 186.523M |
Revenue Surprise | -1.19% |
Release date | Nov 06, 2024 |
EPS estimate | $0.99 |
EPS actual | $0.96 |
EPS Surprise | -3.03% |
Revenue estimate | 192.077M |
Revenue actual | 188.819M |
Revenue Surprise | -1.70% |
Release date | Aug 07, 2024 |
EPS estimate | $0.770 |
EPS actual | $0.94 |
EPS Surprise | 22.08% |
Revenue estimate | 170.94M |
Revenue actual | 182.394M |
Revenue Surprise | 6.70% |
Last 4 Quarters for Amphastar Pharmaceuticals
Below you can see how AMPH performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Release date | Aug 07, 2024 |
Fiscal end date | Jun 30, 2024 |
Price on release | $38.89 |
EPS estimate | $0.770 |
EPS actual | $0.94 |
EPS surprise | 22.08% |
Date | Price |
---|---|
Aug 01, 2024 | $42.45 |
Aug 02, 2024 | $41.57 |
Aug 05, 2024 | $40.41 |
Aug 06, 2024 | $39.40 |
Aug 07, 2024 | $38.89 |
Aug 08, 2024 | $44.06 |
Aug 09, 2024 | $42.85 |
Aug 12, 2024 | $43.25 |
Aug 13, 2024 | $43.56 |
4 days before | -8.39% |
4 days after | 12.01% |
On release day | 13.29% |
Change in period | 2.61% |
Release date | Nov 06, 2024 |
Fiscal end date | Sep 30, 2024 |
Price on release | $53.40 |
EPS estimate | $0.99 |
EPS actual | $0.96 |
EPS surprise | -3.03% |
Date | Price |
---|---|
Oct 31, 2024 | $50.53 |
Nov 01, 2024 | $50.73 |
Nov 04, 2024 | $50.59 |
Nov 05, 2024 | $51.56 |
Nov 06, 2024 | $53.40 |
Nov 07, 2024 | $46.09 |
Nov 08, 2024 | $48.31 |
Nov 11, 2024 | $48.57 |
Nov 12, 2024 | $47.71 |
4 days before | 5.68% |
4 days after | -10.66% |
On release day | -13.69% |
Change in period | -5.58% |
Release date | Feb 27, 2025 |
Fiscal end date | Dec 31, 2024 |
Price on release | $31.49 |
EPS estimate | $1.01 |
EPS actual | $0.92 |
EPS surprise | -8.91% |
Date | Price |
---|---|
Feb 21, 2025 | $31.28 |
Feb 24, 2025 | $32.29 |
Feb 25, 2025 | $31.99 |
Feb 26, 2025 | $31.21 |
Feb 27, 2025 | $31.49 |
Feb 28, 2025 | $28.43 |
Mar 03, 2025 | $27.52 |
Mar 04, 2025 | $27.62 |
Mar 05, 2025 | $28.06 |
4 days before | 0.671% |
4 days after | -10.89% |
On release day | -9.72% |
Change in period | -10.29% |
Release date | May 07, 2025 |
Fiscal end date | Mar 31, 2025 |
Price on release | $24.43 |
EPS estimate | $0.660 |
EPS actual | $0.740 |
EPS surprise | 12.12% |
Date | Price |
---|---|
May 01, 2025 | $23.88 |
May 02, 2025 | $24.50 |
May 05, 2025 | $25.12 |
May 06, 2025 | $23.87 |
May 07, 2025 | $24.43 |
May 08, 2025 | $24.65 |
May 09, 2025 | $24.11 |
May 12, 2025 | $24.34 |
May 13, 2025 | $23.88 |
4 days before | 2.30% |
4 days after | -2.25% |
On release day | 0.90% |
Change in period | 0% |
Amphastar Pharmaceuticals Earnings Call Transcript Summary of Q1 2025
Amphastar Pharmaceuticals Q1 Earnings Call Summary for Investors
Key Financial Highlights:
- Revenue: Q1 net revenues totaled $170.5 million, a decline of 1% from the previous year. Factors contributing to the decline include increased competition affecting critical care products like Glucagon and Epinephrine.
- Product Performance:
- BAQSIMI: Revenues increased 177% to $38.3 million, attributed to Amphastar assuming full control over distribution after transitioning from Lilly.
- Primatene MIST: Achieved sales of $29 million, marking a 20% growth compared to $24 million in Q1 of the previous year.
- Glucagon Injection: Saw a significant decrease of 27% to $20.8 million due to heightened competition.
- Epinephrine Sales: Declined 29% to $18.6 million also affected by competitive pressures.
Cost and Margins:
- Cost of Revenues: Increased to $85.3 million, with a gross margin declining to 50% compared to 52.4% in Q1 of 2024. This decline is primarily due to the distribution shift for BAQSIMI and pricing pressures in competitive markets.
- Net Income: Decreased to $25.3 million (or $0.51 per share), down from $43.2 million (or $0.81 per share) the previous year.
Strategic Developments:
- Amphastar’s initiative to prevent drug shortages was acknowledged, earning the Drug Shortage Assistance Award from the USFDA.
- Pipeline Focus: The company is optimistic about their pipeline, particularly the FDA communications regarding their drug AMP-002. Upcoming ANDA filings include:
- AMP-007 (inhalation product) response planned for Q2.
- AMP-015 (Teriparatide) expected to maintain GDUFA goal date in Q4.
- AMP-018 (GLP-1 product) response to CRL expected in the second half of the year.
Market Outlook:
- The regulatory landscape shows no significant delays in review times for complex generics, allowing for potential product launches later in the year which could support flat revenue expectations.
- The company anticipates that ongoing competition in the Glucagon and Epinephrine markets will be a continuing challenge, while Primatene MIST and BAQSIMI are expected to drive revenue growth.
Tariff Implications:
- Tariffs are monitored but any current impact is minimal, estimated at $500,000 per quarter due to imported active ingredients. The company is well-positioned given its domestic manufacturing capabilities.
Conclusion:
Overall, Amphastar Pharmaceuticals is navigating a challenging competitive environment but remains focused on strategic initiatives and expanding its drug portfolio. Key growth areas like BAQSIMI and Primatene MIST could offer opportunities to offset revenue pressures from other products. Investors may want to monitor the timeline of upcoming regulatory filings and product launches, as well as trends in competitive pressures across the portfolio.